*Q2 FY27 Delay: Manageable Headwind, Not Deal-Breaker* GLEN's capex project faces a one-quarter production commencement delay due to regulatory/monsoon factors. Commercial output shifts from Q1 to Q2 FY27, directly impacting revenue timing and cost absorption. *Revenue Impact:* 3–4 months of production revenue deferred = 5–8% FY27 shortfall (~₹50–80 Cr estimated loss, pending baseline confirmation). Recovery expected FY28 onwards as ramp normalizes. *EBITDA Pressure:* Fixed costs (site, labor, financing) continue unchanged while units produced fall. Margin compression of 200–300 basis points in FY27; absolute EBITDA decline 10–15% if delay holds. Finance costs on capitalized asset further weigh near-term profitability. *Key Risk:* Further delays beyond Q3 FY27 ramp-up could materially worsen payback IRR and trigger covenant concerns if leveraged structure exists. *Strategic Call:* Maintain cautious constructive stance. One-quarter slip is operationally recoverable and margin-cyclical rather than structural. Prioritize Q3 FY27 execution monitoring and capex cost tracking. Recommend hold pending Q2 FY27 operational updates confirming ramp trajectory.

*Q2 FY27 Delay: Manageable Headwind, Not Deal-Breaker* GLEN's capex project faces a one-quarter production commencement delay due to regulatory/monsoon factors. Commercial output shifts from Q1 to Q2 FY27, directly impacting revenue timing and cost absorption. *Revenue Impact:* 3–4 months of production revenue deferred = 5–8% FY27 shortfall (~₹50–80 Cr estimated loss, pending baseline confirmation). Recovery expected FY28 onwards as ramp normalizes. *EBITDA Pressure:* Fixed costs (site, labor, financing) continue unchanged while units produced fall. Margin compression of 200–300 basis points in FY27; absolute EBITDA decline 10–15% if delay holds. Finance costs on capitalized asset further weigh near-term profitability. *Key Risk:* Further delays beyond Q3 FY27 ramp-up could materially worsen payback IRR and trigger covenant concerns if leveraged structure exists. *Strategic Call:* Maintain cautious constructive stance. One-quarter slip is operationally recoverable and margin-cyclical rather than structural. Prioritize Q3 FY27 execution monitoring and capex cost tracking. Recommend hold pending Q2 FY27 operational updates confirming ramp trajectory.

*Q2 FY27 Delay: Manageable Headwind, Not Deal-Breaker* GLEN's capex project faces a one-quarter production commencement delay due to regulatory/monsoon factors. Commercial output shifts from Q1 to Q2 FY27, directly impacting revenue timing and cost absorption. *Revenue Impact:* 3–4 months of production revenue deferred = 5–8% FY27 shortfall (~₹50–80 Cr estimated loss, pending baseline confirmation). Recovery expected FY28 onwards as ramp normalizes. *EBITDA Pressure:* Fixed costs (site, labor, financing) continue unchanged while units produced fall. Margin compression of 200–300 basis points in FY27; absolute EBITDA decline 10–15% if delay holds. Finance costs on capitalized asset further weigh near-term profitability. *Key Risk:* Further delays beyond Q3 FY27 ramp-up could materially worsen payback IRR and trigger covenant concerns if leveraged structure exists. *Strategic Call:* Maintain cautious constructive stance. One-quarter slip is operationally recoverable and margin-cyclical rather than structural. Prioritize Q3 FY27 execution monitoring and capex cost tracking. Recommend hold pending Q2 FY27 operational updates confirming ramp trajectory.

*Q2 FY27 Delay: Manageable Headwind, Not Deal-Breaker* GLEN's capex project faces a one-quarter production commencement delay due to regulatory/monsoon factors. Commercial output shifts from Q1 to Q2 FY27, directly impacting revenue timing and cost absorption. *Revenue Impact:* 3–4 months of production revenue deferred = 5–8% FY27 shortfall (~₹50–80 Cr estimated loss, pending baseline confirmation). Recovery expected FY28 onwards as ramp normalizes. *EBITDA Pressure:* Fixed costs (site, labor, financing) continue unchanged while units produced fall. Margin compression of 200–300 basis points in FY27; absolute EBITDA decline 10–15% if delay holds. Finance costs on capitalized asset further weigh near-term profitability. *Key Risk:* Further delays beyond Q3 FY27 ramp-up could materially worsen payback IRR and trigger covenant concerns if leveraged structure exists. *Strategic Call:* Maintain cautious constructive stance. One-quarter slip is operationally recoverable and margin-cyclical rather than structural. Prioritize Q3 FY27 execution monitoring and capex cost tracking. Recommend hold pending Q2 FY27 operational updates confirming ramp trajectory.